In last trading session, Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) saw 0.48 million shares changing hands with its beta currently measuring 0.36. Company’s recent per share
In last trading session, Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) saw 2.84 million shares changing hands with its beta currently measuring 0.36. Company’s recent per share
Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) has a beta value of 0.36 and has seen 2.45 million shares traded in the recent trading session. The company,
During the last session, Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI)’s traded shares were 0.72 million, with the beta value of the company hitting 0.43. At the
During the last session, Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI)’s traded shares were 1.07 million, with the beta value of the company hitting 0.43. At the
Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI)’s traded shares stood at 0.31 million during the last session, with the company’s beta value hitting 0.35. At the close
Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI)’s traded shares stood at 1.21 million during the last session, with the company’s beta value hitting 0.36. At the close
Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI)’s traded shares stood at 0.52 million during the latest session, with the company’s beta value hitting 0.36. At the last
Marketing Sentinel delivers exclusive content, news, articles, and comprehensive coverage of events in the USA and worldwide with a commitment to reliability, objectivity, and timeliness.
© 2024, Powered by Smart TechOne
